Riding against the wind: a review of competition cycling aerodynamics

Aerodynamics has such a profound impact on cycling performance at the elite level that it has infiltrated almost every aspect of the sport from riding position and styles, equipment design and selection, race tactics and training regimes, governing rules and regulations to even the design of new velodromes. This paper presents a review of the aspects of aerodynamics that are critical to understanding flows around cyclists under racing conditions, and the methods used to evaluate and improve aerodynamic performance at the elite level. The fundamental flow physics of bluff body aerodynamics and the mechanisms by which the aerodynamic forces are imparted on cyclists are described. Both experimental and numerical techniques used to investigate cycling aerodynamic performance and the constraints on implementing aerodynamic saving measures at the elite level are also discussed. The review reveals that the nature of cycling flow fields are complex and multi-faceted as a result of the highly three-dimensional and variable geometry of the human form, the unsteady racing environment flow field, and the non-linear interactions that are inherent to all cycling flows. Current findings in this field have and will continue to evolve the sport of elite cycling while also posing a multitude of potentially fruitful areas of research for further gains in cycling performance

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

BACKGROUND: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. METHODS: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). FINDINGS: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29-146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0- 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25-1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39-1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65-1·60]; p=0·92). INTERPRETATION: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention. FUNDING: British Heart Foundation

Dominant flow structures in the wake of a cyclist

In this wind tunnel investigation the time-averaged wake structure is analyzed for a full scale cyclist mannequin over a complete crank cycle. At typical elite level road cycling speeds, detailed velocity field measurements were performed by traversing a four-hole dynamic pressure probe in planes behind the mannequin for 15° increments in crank position. They highlight the complexity of flows associated with cyclist geometries and show that variations in drag with leg position are primarily attributed to changes in the flow regime and not frontal surface area. The wake is shown to be highly three-dimensional with the primary flow structures consisting of multiple streamwise vortices. The formation strength and interaction of these structures about the center plane of the mannequin depend on whether each leg is in an up or down position around the crank cycle. This dependence on the position of each leg results in an asymmetrical wake configuration for the majority of crank positions tested. This is further highlighted in a series of flow visualization studies showing the origin and asymmetry in the formation of these structures over the upper body with crank position. This work highlights the importance of considering multiple flow regimes when investigating the aerodynamic performance of cyclists.</p

Dominant flow structures in the wake of a cyclist

In this wind tunnel investigation the time-averaged wake structure is analyzed for a full scale cyclist mannequin over a complete crank cycle. At typical elite level road cycling speeds, detailed velocity field measurements were performed by traversing a four-hole dynamic pressure probe in planes behind the mannequin for 15° increments in crank position. They highlight the complexity of flows associated with cyclist geometries and show that variations in drag with leg position are primarily attributed to changes in the flow regime and not frontal surface area. The wake is shown to be highly three-dimensional with the primary flow structures consisting of multiple streamwise vortices. The formation strength and interaction of these structures about the center plane of the mannequin depend on whether each leg is in an up or down position around the crank cycle. This dependence on the position of each leg results in an asymmetrical wake configuration for the majority of crank positions tested. This is further highlighted in a series of flow visualization studies showing the origin and asymmetry in the formation of these structures over the upper body with crank position. This work highlights the importance of considering multiple flow regimes when investigating the aerodynamic performance of cyclists.</p

Dynamic leg-motion and its effect on the aerodynamic performance of cyclists

In this wind-tunnel based experimental study, the flow topology of the near wake of a generic anatomically accurate model cyclist is mapped for a range of reduced pedalling frequencies. Wake flow fields for both static leg and pedalling cyclists are compared over the full 360° rotation of the crank using both time- and phase-averaging. The primary wake flow structures and aerodynamic forces are quantified and analysed under dynamic pedalling conditions representative of an elite-level time-trial cyclist. Over the range of reduced pedalling frequencies studied, only minor variation was detected between the instantaneous drag and primary vortical structures of a pedalling cyclist compared to a stationary cyclist with the pedals in the same position. A simplified model of the aerodynamic forces acting on the legs under motion is presented to provide insight into how the motion of the legs influences aerodynamic drag. A comparison of predicted forces from this model with those from experiments provides a new perspective on how the aerodynamics of cyclists may be optimised.</p

A numerical model for the time-dependent wake of a pedalling cyclist

A method for computing the wake of a pedalling cyclist is detailed and assessed through comparison with experimental studies. The large-scale time-dependent turbulent flow is simulated using the Scale Adaptive Simulation approach based on the Shear Stress Transport Reynolds-averaged Navier–Stokes model. Importantly, the motion of the legs is modelled by joining the model at the hips and knees and imposing solid body rotation and translation to the lower and upper legs. Rapid distortion of the cyclist geometry during pedalling requires frequent interpolation of the flow solution onto new meshes. The impact of numerical errors, that are inherent to this remeshing technique, on the computed aerodynamic drag force is assessed. The dynamic leg simulation was successful in reproducing the oscillation in the drag force experienced by a rider over the pedalling cycle that results from variations in the large-scale wake flow structure. Aerodynamic drag and streamwise vorticity fields obtained for both static and dynamic leg simulations are compared with similar experimental results across the crank cycle. The new technique presented here for simulating pedalling leg cycling flows offers one pathway for improving the assessment of cycling aerodynamic performance compared to using isolated static leg simulations alone, a practice common in optimising the aerodynamics of cyclists through computational fluid dynamics.</p